Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Press Release
Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Reimagining healthcare in challenging times: Novartis in Society US
Article
Novartis is building a leading focused medicines company powered by advanced therapy platforms and data science. At the same time, we are pursuing innovative approaches to making pharmaceuticals more affordable and accessible and strengthening our communities and society. Since 2016, we have published an annual Novartis in Society US Report, which details our goals and activities in support of patients and their families, healthcare providers, the communities where we live and work, and our healthcare system.
At Novartis, we work to build trust with society and deliver long-term value to our stakeholders by embedding environmental, social and governance (ESG) topics into the core of our business strategy and operations. As a global company, we have a great responsibility and an even greater opportunity to lead the world in creating positive social change. We can help catalyze a global response to complex challenges, such as the current pandemic or climate change, by embracing societal impact as a core business objective.
Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years
Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by March 1, 2021
Press Release
Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years
Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by March 1, 2021
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid
Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually1
Agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral across its operations by 2025 and across its supply chain by 2030
Results from the Novartis Foundation-initiated Leprosy Post-Exposure Prophylaxis (LPEP) program covered more than 150,000 people across seven countries
Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programs, and is generally well accepted by patients, their contacts, and health-care workers
Novartis has been committed to eliminating leprosy for over 30 years, with its multidrug therapy for the disease donated for free to over 7m patients since 2000
Press Release
Results from the Novartis Foundation-initiated Leprosy Post-Exposure Prophylaxis (LPEP) program covered more than 150,000 people across seven countries
Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programs, and is generally well accepted by patients, their contacts, and health-care workers
Novartis has been committed to eliminating leprosy for over 30 years, with its multidrug therapy for the disease donated for free to over 7m patients since 2000
October 1, 2020 /3BL Media/ - OLON announced it will continue its collaboration with Novartis to support the Africa Sickle Cell Disease program as it expands to Kenya, Uganda and Tanzania. Initially launched in 2019 by Novartis and its partners in Ghana, the Africa Sickle Cell Disease program intends to improve the lives of people with sickle cell disease and accelerate access to treatment and related laboratory tests.
September 30, 2020 /3BL Media/ - COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide.
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice
Commitment to include partnerships and support to address the underrepresentation of minorities, including African American/Black and Hispanic communities, in clinical trials
Reinforces US Foundation focus on improving health by strengthening health systems, eliminating barriers to care and addressing social determinants of health
Press Release
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice
Commitment to include partnerships and support to address the underrepresentation of minorities, including African American/Black and Hispanic communities, in clinical trials
Reinforces US Foundation focus on improving health by strengthening health systems, eliminating barriers to care and addressing social determinants of health
